To determine the finalists and the awardee, the GCG implemented a three-stage validation process consisting of initial screening, stakeholder evaluation and shortlisting by the Selection Committee.
Lei Qian, Chief R&D Officer of General Biomedicine at Innovent Biologics, stated, "Mazdutide is the world's first approved GCG/GLP-1 dual receptor agonist for both glycemic control and weight management.
GCG & Packable Alliance. This collaboration is part of GCG's strategy to expand the capabilities of one of its operating companies, Archway, with fast fulfillment and nationwide delivery to retail stores and homes.